arrow
V

Vicente Alonso

Hospital Universitario Miguel Servet
H指数:26
被引数:2,870

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perioperative Chemotherapy and Long-Term Cure in Resected Grade 3 Gastroenteropancreatic Neuroendocrine Carcinomas: The GETNE SOUTH-NEC Study

围手术期化疗与切除后3级胃肠胰神经内分泌癌的长期治愈:GETNE SOUTH-NEC研究

2026-10-080
OAAI
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study

胃肠胰腺神经内分泌肿瘤患者营养不良和肌少症预测工具:NUTRIGETNE (GETNE-S2109) 研究结果

2026-05-270
OAAI
Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

更正:高血压作为贝伐珠单抗含药一线疗法在转移性乳腺癌和结直肠癌中的预测因素(BRECOL [GEICAM/2011-04] 研究)。

2025-11-250
OAAI
Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors

卢德替昂-177(Lutetium-177 Dotatate)治疗转移性神经内分泌肿瘤的真实世界疗效与安全性评估

2025-03-300
OA
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study

西班牙晚期胃肠胰神经内分泌肿瘤患者的营养状况和生活质量:NUTRIGETNE (GETNE-S2109) 研究

2025-02-250
OA
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)
2024-08-080
OAAI
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours (vol 188, pg 39, 2023)
2024-05-010
OA
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
2024-01-082
PRE
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
2023-07-056
PRE
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

晚期胃肠胰腺神经内分泌肿瘤患者多激酶抑制剂毒性的性别差异

2023-07-017
OAAI
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
2022-09-0813
OA
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
2021-01-2811
OA
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
2019-09-0329
OAAI
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
2018-07-019
OAAI
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
2017-11-0963
OAAI
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience

卡培他滨和替莫唑胺治疗1/2级神经内分泌肿瘤: 西班牙多中心经验

2016-11-0238
PREAI
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
2015-07-0424
OAAI